To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05166577
Title Nanatinostat Plus Valganciclovir in Patients With Advanced EBV+ Solid Tumors, and in Combination With Pembrolizumab in EBV+ RM-NPC
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Viracta Therapeutics, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | CAN | AUS

Facility Status City State Zip Country Details
Stanford Cancer Center Stanford California 94305 United States Details
University of Colorado Hospital Aurora Colorado 80045 United States Details
University of Texas MD Anderson Cancer Center Houston Texas 77030 United States Details
Blacktown Hospital Blacktown Australia Details
Princess Margaret Cancer Centre Toronto Canada Details
Queen Mary Hospital Hong Kong Hong Kong Details
Prince Of Wales Hospital, The Chinese University Of Hong Kong Sha Tin Hong Kong Details
Samsung Medical Center Seoul Korea, Republic of Details
Sarawak General Hospital Kuching Sarawak Malaysia Details
University of Malaya Medical Centre Kuala Lumpur Malaysia Details
National Cancer Centre Singapore Singapore Singapore Details
Taipei Veterans General Hospital Taipei City Taiwan Details
Linkou Chang Gung Memorial Hospital Taoyuan City Taiwan Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field